Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Office of Rare Diseases (ORD).
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Office of Rare Diseases (ORD)
Collaborator:
FDA Office of Orphan Products Development
Information provided by:
Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:
NCT00414648
First received: December 20, 2006
Last updated: August 27, 2009
Last verified: August 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Lymphangioleiomyomatosis (LAM) is a rare lung disease that is caused by genetic mutations. It results in the uncontrolled growth and proliferation of an unusual type of smooth muscle cell. These cells invade lung tissue, including the airways, blood vessels, and lymph vessels, and restrict the flow of air, blood, and lymph, respectively. Respiratory failure, lung collapse (pneumothorax), and pleural effusions (chylothorax) are hallmarks of the disease. This study will evaluate the safety and effectiveness of sirolimus, an immunosuppressive medication, in stabilizing or improving lung function in people with LAM.
| Condition | Intervention | Phase |
|---|---|---|
|
Lymphangioleiomyomatosis |
Drug: Sirolimus Drug: Placebo sirolimus |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Lymphangioleiomyomatosis Efficacy and Safety Trial |
Resource links provided by NLM:
Genetics Home Reference related topics:
lymphangioleiomyomatosis
MedlinePlus related topics:
Collapsed Lung
U.S. FDA Resources
Further study details as provided by Office of Rare Diseases (ORD):
Primary Outcome Measures:
- FEV1 response [ Time Frame: measured at Month 12 ] [ Designated as safety issue: No ]
- Severity graded adverse events [ Time Frame: measured at Month 12 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- FVC response [ Time Frame: measured at Month 24 ] [ Designated as safety issue: No ]
- Diffusing capacity for carbon monoxide [ Time Frame: measured at Month 24 ] [ Designated as safety issue: No ]
- Lung volume [ Time Frame: measured at Month 24 ] [ Designated as safety issue: No ]
- Distance walked in 6 minutes [ Time Frame: measured at Month 24 ] [ Designated as safety issue: No ]
- Volumetric estimate of lung cyst size and mass of tissue in the chest [ Time Frame: measured at Month 24 ] [ Designated as safety issue: No ]
- Biomarkers [ Time Frame: measured at Month 24 ] [ Designated as safety issue: No ]
- Chylous effusions [ Time Frame: measured at Month 24 ] [ Designated as safety issue: Yes ]
- Pneumothoraces [ Time Frame: measured at Month 24 ] [ Designated as safety issue: Yes ]
- Hemorrhagic renal episodes [ Time Frame: measured at Month 24 ] [ Designated as safety issue: Yes ]
- Mortality [ Time Frame: measured at Month 12 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 120 |
| Study Start Date: | December 2006 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Participants will receive sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
|
Drug: Sirolimus
A sirolimus dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
Other Name: Rapamycin
|
|
Placebo Comparator: 2
Participants will receive placebo sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
|
Drug: Placebo sirolimus
A placebo dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
Other Name: Other names: placebo
|
Detailed Description:
LAM is an uncommon, progressive, cystic lung disease that predominantly affects young women. It is believed to be caused by defects within cellular pathways that regulate nutrient uptake, cell size, cell migration, and cell proliferation. The disease is caused by mutations in tuberous sclerosis complex (TSC) genes. Individuals with LAM often experience pneumothorax and chylothorax, as well progressive loss of lung function. LAM is frequently fatal and existing therapies for the disease have not proven effective. Lung transplantation can be considered as a last option, but alternative treatments are needed. Sirolimus is an immunosuppressive drug that is often used in people who have had kidney transplants. It directly affects the genetic pathway that causes LAM. This study will evaluate the safety and effectiveness of sirolimus in stabilizing or improving lung function in people with LAM.
Individuals interested in participating in this 2-year, double-blind study will first report to the study sites for pulmonary function testing to determine their eligibility for participation. Participants deemed eligible will be randomly assigned to receive either sirolimus or placebo for 1 year. Sirolimus or placebo will be administered in 2 tablet doses (2 mg for sirolimus) for the duration of the study. Study visits will occur at baseline, Week 3, every 3 months for 12 months, and Months 18 and 24. Study visits will include a physical exam, questionnaires, a pregnancy test, blood and urine collection, and functional lung tests. A 6-minute walk test will occur at most study visits; a chest x-ray will be taken at baseline and Month 24; and a volumetric computed tomography scan will occur at baseline, Month 12, and Month 24. Adverse events, medication side effects, and lung function will be assessed at each visit.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 18 or older
- Diagnosis of LAM as determined by a biopsy and chest CT scan; or chest CT scan in the setting of tuberous sclerosis, angiomyomata or chylous pleural effusion; or chest CT scan and a VEGF-D level of at least 800 pg/ml
- Forced expiratory volume in one second (FEV1) of 70% or less of predicted value after administration of a bronchodilator
Exclusion Criteria:
- Known allergy to sirolimus
- History of heart attack, angina, or stroke due to clogging, narrowing, and hardening of the arteries and blood vessels
- Significant hematologic or hepatic abnormality (transaminase levels greater than three times the upper limit of normal, HCT less than 30%, platelets less than 80,000/cubic mm, adjusted absolute neutrophil count less than 1,000/cubic mm, total white blood cell count less than 3,000/cubic mm)
- Intercurrent infection at the time treatment with sirolimus begins
- Any surgery involving entry into a body cavity or requiring three or more sutures within 8 weeks of initiation of study drug
- Use of an investigational drug within the 30 days prior to random assignment
- Uncontrolled hyperlipidemia
- Previous lung transplant or currently on lung transplant list
- Unable to attend scheduled study visits
- Unable to perform pulmonary function tests
- Creatinine levels greater than 2.5 mg/dl
- Chylous ascites severe enough to affect diaphragmatic function
- Pleural effusion severe enough to affect pulmonary function, as determined by the study physician
- History of acute pneumothorax within the 2 months prior to study entry
- History of malignancy within the 2 years prior to study entry (except for squamous or basal cell skin cancer)
- Use of estrogen containing medication within the thirty days prior to randomization
- Unable or unwilling to use adequate contraception
- Pregnant, breastfeeding, or plans to become pregnant within the next 2 years
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00414648
Please refer to this study by its ClinicalTrials.gov identifier: NCT00414648
Locations
| United States, California | |
| University of California Los Angeles | |
| Los Angeles, California, United States, 90024 | |
| United States, Colorado | |
| National Jewish Medical and Research Center | |
| Denver, Colorado, United States, 80206 | |
| United States, Florida | |
| University of Florida, Gainesville | |
| Gainesville, Florida, United States, 32611 | |
| United States, Maryland | |
| National Heart, Lung, and Blood Institute | |
| Bethesda, Maryland, United States, 20892 | |
| United States, Massachusetts | |
| Harvard's Brigham and Women's Hospital | |
| Boston, Massachusetts, United States, 02115 | |
| United States, Ohio | |
| University of Cincinnati Medical Center | |
| Cincinnati, Ohio, United States, 45267 | |
| Cleveland Clinic Foundation | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Oregon | |
| Oregon Health & Science University | |
| Portland, Oregon, United States, 97239 | |
| United States, South Carolina | |
| Medical University of South Carolina | |
| Charleston, South Carolina, United States, 29425 | |
| United States, Texas | |
| University of Texas Health Center at Tyler | |
| Tyler, Texas, United States, 75708 | |
| Canada, Ontario | |
| Toronto General Hospital | |
| Toronto, Ontario, Canada, M5G 2N2 | |
| Japan | |
| National Kinki-Chou Hospital | |
| Sakai, Osaka, Japan, 591-8555 | |
| Niigata University Medical and Dental Hospital | |
| Niigata, Japan, 951-8520 | |
Sponsors and Collaborators
Office of Rare Diseases (ORD)
FDA Office of Orphan Products Development
Investigators
| Principal Investigator: | Frank McCormack, MD | University of Cincinnati Medical Center Division of Pulmonary and Critical Care Medicine |
| Principal Investigator: | Bruce Trapnell, MD | Cincinnati Children's Hospital Medical Center Division of Pulmonary Biology |
More Information
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Frank McCormack, MD, University of Cincinnati Medical Center |
| ClinicalTrials.gov Identifier: | NCT00414648 History of Changes |
| Obsolete Identifiers: | NCT00408343, NCT00720746 |
| Other Study ID Numbers: | RDCRN 5702 RLD 5702 1U54RR019498-01 |
| Study First Received: | December 20, 2006 |
| Last Updated: | August 27, 2009 |
| Health Authority: | United States: Federal Government United States: Food and Drug Administration |
Keywords provided by Office of Rare Diseases (ORD):
|
Lymphangiomyomatosis Lung Disease |
Additional relevant MeSH terms:
|
Lymphangioleiomyomatosis Lymphangiomyoma Lymphatic Vessel Tumors Neoplasms by Histologic Type Neoplasms Perivascular Epithelioid Cell Neoplasms Neoplasms, Connective and Soft Tissue Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
Sirolimus Everolimus Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic Antineoplastic Agents Antifungal Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on September 23, 2016